RecruitingPhase 2NCT05742698

Nabilone for Agitation in Frontotemporal Dementia

Double Blind Crossover Clinical Trial of Nabilone for Agitation in Frontotemporal Dementia

Sponsor

Simon Ducharme, MD

Enrollment

45 participants

Start Date

Mar 7, 2023

Study Type

INTERVENTIONAL

Conditions

Frontotemporal Dementia Primary Progressive Aphasia FTD Frontotemporal Dementia, Behavioral Variant bvFTD PPA

Summary

The primary goal of this study is to test the hypothesis that oral nabilone treatment will reduce agitation compared with placebo in patients with Frontotemporal Dementia (both behavioural variant frontotemporal dementia and primary progressive aphasia). The study population is defined as patients with probable Frontotemporal Dementia that meet the International Psychogeriatric Association criteria for agitation in cognitive disorders.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Nabilone and a drug called Placebo for people with ftd, frontotemporal dementia, and other related conditions. The study is currently recruiting participants at 7 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNabilone

Nabilone is a synthetic cannabinoid that has shown benefit for agitation in Alzheimer's disease. Nabilone further has potentially beneficial properties on oxidative stress and inflammation in neurodegenerative diseases, mechanisms that have been linked to the pathophysiology of frontotemporal dementia.

DRUGPlacebo

The placebo is a capsule identical to the nabilone capsules that will be used in this clinical trial.